Convatec Group Acquires Triad Life Sciences

Integra LifeSciences Acquires ACell, Inc.

December 16, 2020

Medical Devices

Integra LifeSciences agreed to acquire regenerative-medicine company ACell, Inc. for $300 million upfront in cash plus up to $100 million in revenue-based milestones. The acquisition adds ACell's MatriStem porcine urinary bladder matrix platform to Integra's tissue technologies portfolio and is expected to close in Q1 2021, subject to customary conditions.

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.

Solventum Completes Acquisition of Acera Surgical

December 23, 2025

Healthcare Services

Solventum completed its acquisition of Acera Surgical, a privately held bioscience company focused on regenerative wound care. The deal includes $725 million in upfront cash plus up to $125 million in contingent cash payments tied to future milestones.

Triad Technologies Acquires Tech-Syn Corporation

September 26, 2023

Industrial Services

Triad Technologies, LLC completed the acquisition of Tech-Syn Corporation (effective March 31, 2023), expanding Triad's product offering and Midwest footprint. The transaction, executed by Vandalia, Ohio-based Triad (which is PE-backed by Shorehill Capital LLC), adds Tech-Syn's value-added sealing, O-ring and hose capabilities across locations in Bloomingdale and Rockford, Illinois and Milwaukee, Wisconsin.

Mercalis (formerly TrialCard) Acquires Triangle Insights Group

April 12, 2022

Healthcare Services

Mercalis (formerly TrialCard) acquired Triangle Insights Group, a Durham-based life sciences strategy consulting firm, to expand its commercialization capabilities. The transaction is an add-on to the Mercalis platform (which is backed by Odyssey Investment Partners) and will retain all TIG partners and employees as Mercalis integrates strategic insights, pricing and market access expertise into its full-service commercialization offering.

Collagen Matrix Acquires Polyganics

October 5, 2022

Medical Devices

Collagen Matrix, a Linden Capital Partners portfolio company, has acquired Polyganics B.V., a Netherlands-based developer and manufacturer of bioresorbable medical devices. The add-on acquisition expands Collagen Matrix's regenerative medicine and polymer capabilities, entering new clinical verticals such as ENT and general surgery and broadening its neurosurgery and peripheral nerve offerings.